1172131-64-4

Basic information

• Product Name: 2-(2-Aminopropan-2-yl)-4-((4-fluorobenzyl)carbamoyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-5-yl 2,2-dimethylpropanoate
• Synonyms: 1172131-64-4;EC 620-134-9;Propanoic acid, 2,2-dimethyl-, 2-(1-amino-1-methylethyl)-4-[[[(4-fluorophenyl)methyl]amino]carbonyl]-1,6-dihydro-1-methyl-6-oxo-5-pyrimidinyl ester;2-(2-Aminopropan-2-yl)-4-((4-fluorobenzyl)carbamoyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-5-yl 2,2-dimethylpropanoate;SCHEMBL3733388;DTXSID501009959;[2-(2-aminopropan-2-yl)-4-[(4-fluorophenyl)methylcarbamoyl]-1-methyl-6-oxopyrimidin-5-yl] 2,2-dimethylpropanoate;2-(2-Amino-2-propanyl)-4-[(4-fluorobenzyl)carbamoyl]-1-methyl-6-oxo-1,6-dihydro-5-pyrimidinyl pivalate
• CAS NO: 1172131-64-4
• Molecular Weight: 418.468
• EINECS: -0
• Mol File: 1172131-64-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-(2-Aminopropan-2-yl)-4-((4-fluorobenzyl)carbamoyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-5-yl 2,2-dimethylpropanoate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-Aminopropan-2-yl)-4-((4-fluorobenzyl)carbamoyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-5-yl 2,2-dimethylpropanoate(1172131-64-4)
• EPA Substance Registry System: 2-(2-Aminopropan-2-yl)-4-((4-fluorobenzyl)carbamoyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-5-yl 2,2-dimethylpropanoate(1172131-64-4)

Safety Data

• Hazardous Substances Data: 1172131-64-4(Hazardous Substances Data)

Usage

General Description

2-(2-Aminopropan-2-yl)-4-((4-fluorobenzyl)carbamoyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-5-yl 2,2-dimethylpropanoate is a chemical compound that belongs to the class of dihydropyrimidines. It is a derivative of 2,2-dimethylpropanoic acid and contains a substituted pyrimidine ring with an aminopropan-2-yl group and a fluorobenzylcarbamoyl group attached at position 4. 2-(2-Aminopropan-2-yl)-4-((4-fluorobenzyl)carbamoyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-5-yl 2,2-dimethylpropanoate has potential application in pharmaceuticals and may exhibit biological activities due to its structural properties. Further studies may be needed to better understand its potential uses and effects.

Upstream product

• 519028-33-2 benzyl 2-(4-(4-fluorobenzylcarbamoyl)-5-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-ylcarbamate 
• 518048-02-7 {1-[4-(4-fluoro-benzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidin-2-yl]-1-methyl-ethyl}carbamic acid benzyl ester 
• 3282-30-2 pivaloyl chloride 
• 140-75-0 para-fluorobenzylamine 
• 888504-27-6 2-(1-benzyloxycarbonylamino-1-methyl-ethyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid methyl ester 
• 519028-33-2 {1-[4-(4-fluoro-benzylcarbamoyl)-5,6-dihydroxy-pyrimidin-2-yl]-1-methyl-ethyl}-carbamic acid benzyl ester 
• 1172131-65-5 C₂₉H₃₃FN₄O₆ 

Downstream Products

• 1172131-66-6 C₂₅H₂₉FN₆O₆ 
• 518048-05-0 raltegravir 
• 1391918-17-4 C₂₀H₂₃FN₆O₆ 
• 1391918-18-5 C₃₄H₃₆F₂N₈O₈ 

Relevant articles and documents

PROCESSES FOR PREPARING RALTEGRAVIR AND INTERMEDIATES IN THE PROCESSES

The present invention provides a process for preparing benzyl-2-(4-(4- fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2- ylcarbamate (RLT-8), a process for preparing Raltegravir via RLT-8, a process for preparing methyl 2-(2-(benzyloxycarbonylamino)propan-2-yl)-5 -hydroxy-1-methyl-6- oxo-1,6-dihydropyrimidine-4-carboxylate (RLT-7'), a process for preparing Raltegravir via RLT-7', and a process for preparing crystalline form V of Raltegravir potassium.

Development of a second-generation, highly efficient manufacturing route for the HIV integrase inhibitor raltegravir potassium

A manufacturing route for the synthesis of raltegravir potassium 1 was developed via a thermal rearrangement of amidoxime DMAD adducts 6 to construct the key, highly functionalized hydroxypyrimidinone core 7. Utilizing this route 1 was prepared in nine linear chemical steps with 22% overall yield. A second-generation synthesis was subsequently developed that solved the key chemical, productivity, and environmental impact issues of the initial synthesis. Highlights of the new synthesis include a highly selective methylation, 3-4-fold higher productivity, and a 65% reduction of combined organic and aqueous waste produced. The efficient second-generation manufacturing route provides raltegravir potassium 1 in 35% overall yield.